G
Grace Therapeutics Inc D
D
GRCE
2.38000
USD
-0.03
(-1.24%)
Market Open
Volume
1,069
EPS
-1
Div Yield
-
P/E
-5
Market Cap
38,732,182
Title: Grace Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipinefor the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.